Imugene Ltd has secured a patent in India for its exclusively licensed CF33 oncolytic virotherapy technology.
Issued under patent number 558994, the patent provides 20 years of protection from its filing date of August 9, 2017.
This patent adds to Imugene’s existing intellectual property portfolio, which includes patents granted in the United States (September 10, 2024, Pat. No. 12,084,687) and Japan (Patent Application No. 2023-200433) within the same oncolytic virotherapy patent family.
The CF33 oncolytic virus, a chimeric vaccinia poxvirus, was developed by Professor Yuman Fong, chair of Surgical Oncology at City of Hope and a leading expert in oncolytic virus research.
Oncolytic viruses selectively target and destroy cancer cells while stimulating an immune response, potentially enhancing clinical outcomes for patients.
Protect and advance
The company continues to strengthen its efforts to protect and advance its CF33 oncolytic virotherapy as it progresses through clinical development.
“The grant of this India patent is another significant step in expanding global protection for CF33, building on our strong foundation in key markets such as the US and Japan,” Imugene managing director and CEO Leslie Chong said.
“We remain committed to advancing our oncolytic virotherapy pipeline and delivering next-generation immunotherapies to patients worldwide.”
The India patent comes just days after news dropped that Imugene had received a notice of allowance from the Chinese Patent Office, securing intellectual property protection in China, the largest market in Asia.
The protection applies to patent application number 201880064280.9, covering the CD19-expressing oncolytic virus, onCARlytics.
Titled “Oncolytic Virus Expressing a CAR-T Cell Target and Uses Thereof”, the patent safeguards the composition and method of use of onCARlytics, extending protection through to 2038.
Read more: Imugene secures CD19 oncolytic virus patent in China